Patients can now explore peptide therapy with licensed providers and receive prescribed medications directly from U.S. 503A compounding pharmacies.

CORTLAND, Ohio, Nov. 5, 2026 /PRNewswire/ — Amble Health today announced expanded patient access to six compounded peptide options: BPC-157, TB-500, MOTS-c, Epitalon, Semax, and KPV, following a new interim policy from the U.S. Department of Health and Human Services (HHS).

Through the program, patients complete an online health assessment and consult with a licensed healthcare provider who reviews their medical history, discusses health goals, and determines whether treatment is appropriate. When prescribed, medications are prepared by a state-licensed 503A compounding pharmacy and shipped directly to the patient’s door with clear instructions and ongoing support.

Prioritizing Regulated Sourcing and Oversight

While some online vendors sell unverified peptides labeled for “research use only” without a prescription, often requiring buyers to reconstitute powders themselves without reliable testing data, Amble Health provides a strictly regulated, prescription-based pathway.

Under the new HHS interim policy, participating 503A pharmacies operate under state oversight and applicable federal requirements, adhering to rigorous standards for active pharmaceutical ingredients (APIs):

• Identified Manufacturing: Original ingredient manufacturers must be registered with the FDA and meet strict drug manufacturing standards.
• Documented Testing: Every ingredient batch requires a valid Certificate of Analysis verifying identity, strength, purity, and the absence of harmful contaminants.
• Individual Prescriptions: Each medication is compounded specifically for an individual patient under a licensed provider’s directive.

“For patients exploring peptide therapy, knowing where a medication comes from and having clinician guidance are essential,” said Joey Stiver, CEO of Amble Health. “Our platform replaces guesswork with a structured pathway, connecting patients to licensed providers and state-regulated pharmacies that meet strict ingredient and testing standards.”

Important Safety Information

The HHS interim policy provides a defined path from medical review to pharmacy preparation, though it does not constitute FDA approval. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality prior to marketing, and clinical research in humans remains limited. Amble Health encourages anyone considering peptide therapy to consult a physician to weigh available evidence, health history, and treatment options.

To learn more or begin an online medical review, visit joinamble.com.

About Amble Health

Amble Health is a telehealth platform dedicated to accessible, personalized online medical care, connecting patients nationwide with licensed clinicians and regulated U.S. compounding pharmacies.

View original content:https://www.prnewswire.com/news-releases/amble-health-launches-six-compounded-peptide-options-through-online-medical-care-302931314.html

SOURCE Amble Health